Prostatitis

1. Clinical Overview

Summary

Prostatitis represents a spectrum of inflammatory and pain syndromes affecting the prostate gland, ranging from life-threatening acute bacterial infection to the enigmatic chronic pelvic pain syndrome (CPPS). The National Institutes of Health (NIH) classification system, established in 1999, divides prostatitis into four distinct categories based on clinical presentation, microbiological findings, and inflammatory markers. [1]

Type I (Acute Bacterial Prostatitis) is a urological emergency characterised by acute systemic infection with fever, rigors, and an exquisitely tender prostate. This represents approximately 5-10% of cases and requires urgent hospitalisation with intravenous antibiotics. [2]

Type II (Chronic Bacterial Prostatitis) accounts for 5-10% of cases and presents as recurrent urinary tract infections caused by the same bacterial organism, with bacteria persistently colonising the prostate despite antibiotic therapy. [3]

Type III (Chronic Pelvic Pain Syndrome) is the most common variant, representing approximately 90-95% of all prostatitis cases. CPPS is characterised by chronic pelvic, perineal, or genital pain lasting at least 3 months in the absence of identifiable bacterial infection. This condition significantly impacts quality of life and remains one of the most challenging conditions in urology to diagnose and treat. [4,5]

Type IV (Asymptomatic Inflammatory Prostatitis) is an incidental finding of prostatic inflammation discovered during evaluation for other conditions (such as infertility or elevated PSA) without any symptoms attributable to the prostate. [1]

The aetiology varies dramatically between categories. Acute and chronic bacterial prostatitis are predominantly caused by uropathogenic Escherichia coli (70-80% of cases), with other Gram-negative organisms including Klebsiella, Pseudomonas, and Enterobacter accounting for most remaining cases. [6] In contrast, CPPS has a poorly understood, likely multifactorial aetiology involving neuromuscular, immunological, and psychological factors. [7]

Management approaches differ fundamentally between categories. Bacterial prostatitis requires prolonged antibiotic therapy (typically 4-6 weeks) with fluoroquinolones or trimethoprim due to poor antibiotic penetration into prostatic tissue. [8] CPPS management necessitates a multimodal approach including alpha-blockers, anti-inflammatory agents, pelvic floor physiotherapy, and psychological support, with variable treatment success rates. [9,10]

Clinical Pearls

Acute Bacterial Prostatitis is a Medical Emergency: Presents with fever, rigors, severe perineal pain, and an acutely tender, boggy prostate on digital rectal examination (DRE). Immediate hospitalisation with IV antibiotics is mandatory due to risk of urosepsis, prostatic abscess, and mortality if untreated. [2]

NEVER Perform Vigorous Prostatic Massage in Acute Prostatitis: While prostatic massage to obtain expressed prostatic secretions (EPS) is valuable in chronic cases, it is absolutely contraindicated in acute bacterial prostatitis due to risk of inducing bacteraemia, septic shock, and potentially fatal complications. DRE should be gentle palpation only. [11]

CPPS Represents 90% of "Prostatitis" Cases: The majority of men presenting with symptoms attributed to "prostatitis" actually have chronic pelvic pain syndrome (Type III). No bacterial pathogen is identified despite extensive investigation. This is a diagnosis of exclusion requiring careful differentiation from bacterial forms. [4,5]

Prolonged Antibiotic Courses are Essential for Bacterial Prostatitis: Due to poor antibiotic penetration into prostatic tissue and formation of bacterial biofilms, treatment duration of 4-6 weeks is required for bacterial prostatitis. Shorter courses result in high relapse rates and development of chronic infection. [8,12]

Suprapubic Catheterisation for Acute Retention: If acute urinary retention complicates acute bacterial prostatitis, suprapubic catheterisation is strongly preferred over urethral catheterisation to avoid traumatising the inflamed, oedematous prostate and potentially seeding infection. [13]

PSA Elevation is Expected in Acute Prostatitis: Prostate-specific antigen (PSA) levels are frequently elevated during acute prostatic inflammation and should not be interpreted as suggesting malignancy. PSA testing for cancer screening should be deferred until at least 4-6 weeks after resolution of acute infection. [14]

Fluoroquinolones Achieve Best Prostatic Penetration: Among antibiotics, fluoroquinolones (particularly ciprofloxacin and levofloxacin) achieve the highest concentrations in prostatic tissue and fluid, making them first-line agents for bacterial prostatitis. However, increasing antimicrobial resistance necessitates culture-guided therapy. [15]

CPPS Requires Multimodal Treatment: No single therapy is effective for chronic pelvic pain syndrome. Evidence supports combination approaches including alpha-blockers (tamsulosin), anti-inflammatory agents, pelvic floor physiotherapy, cognitive behavioural therapy, and neuromodulatory medications. Setting realistic patient expectations is crucial. [9,10,16]

---

2. Epidemiology

Incidence and Prevalence

Prostatitis represents one of the most common urological conditions affecting men, accounting for approximately 8% of all urology consultations and 1% of all primary care consultations in developed nations. [17]

Distribution by NIH Category

Exam Detail: The distribution of prostatitis categories varies between healthcare settings, with community urological practice showing different patterns compared to specialist chronic pain clinics.

Risk Factors

Acute and Chronic Bacterial Prostatitis

Chronic Pelvic Pain Syndrome (CPPS)

The aetiology of CPPS remains poorly understood, with likely heterogeneous pathophysiology varying between patients. [7]

Geographic and Demographic Variations

• Age Distribution: CPPS predominantly affects men aged 30-50 years, whereas acute bacterial prostatitis has bimodal distribution with peaks in young sexually active men and older men with BPH. [18]
• Racial Differences: Some studies suggest higher prevalence of prostatitis symptoms in Caucasian and Asian populations compared to African-American men, though confounding factors limit interpretation. [25]
• Socioeconomic Factors: Access to healthcare and antibiotic availability influence progression from acute to chronic bacterial prostatitis in resource-limited settings. [17]

---

3. Aetiology and Pathophysiology

Bacterial Prostatitis (Types I and II)

Microbiology

Bacterial prostatitis results from infection with uropathogenic organisms, predominantly Gram-negative enteric bacteria. [6]

Exam Detail: Uropathogenic E. coli (UPEC) Virulence Factors:

E. coli strains causing prostatitis possess specific virulence factors enabling prostatic colonisation:

1. P-fimbriae (Pili): Adhesins that bind to uroepithelial cells and facilitate ascent into prostatic ducts.
2. Haemolysin: Cytotoxic protein causing tissue damage and inflammation.
3. Aerobactin: Iron acquisition system enabling bacterial survival in iron-limited prostatic environment.
4. Capsular Polysaccharides: Inhibit phagocytosis and complement-mediated killing.

These virulence factors explain why certain E. coli strains cause prostatitis while commensal strains do not. [6]

Routes of Infection

Pathophysiology of Acute Bacterial Prostatitis

1. Initial Infection: Uropathogenic bacteria (typically E. coli) ascend through prostatic ducts or reflux of infected urine occurs during turbulent voiding.

2. Acute Inflammation: Bacterial colonisation triggers intense neutrophilic inflammatory response with prostatic oedema, congestion, and increased vascular permeability. [2]

3. Prostatic Swelling: Marked oedema can cause urethral compression and acute urinary retention. Gland becomes exquisitely tender and boggy on examination. [2]

4. Systemic Response: Bacterial endotoxins (especially lipopolysaccharide from Gram-negative organisms) trigger systemic inflammatory response with fever, rigors, and potential progression to sepsis/septic shock. [2]

5. Complications: Without prompt treatment, potential for prostatic abscess formation (5-10% of cases), chronic bacterial prostatitis (persistence despite treatment), or urosepsis with multi-organ failure. [2,13]

Pathophysiology of Chronic Bacterial Prostatitis

Chronic bacterial prostatitis develops when bacteria persist in prostatic tissue despite antibiotic therapy. Several mechanisms explain bacterial persistence: [3,12]

1. Poor Antibiotic Penetration: The prostate has blood-prostate barrier limiting antibiotic diffusion. Lipophilic antibiotics (fluoroquinolones, trimethoprim, macrolides) penetrate better than hydrophilic agents (beta-lactams). [12]

2. Bacterial Biofilms: Bacteria form biofilm communities within prostatic acini, protected from antibiotics and host immune responses. Biofilms can be 100-1000 times more resistant to antibiotics than planktonic bacteria. [3]

3. Prostatic Calculi: Calcified deposits within prostatic ducts harbour bacteria in protected niches inaccessible to antibiotics and immune cells. [3]

4. Anatomical Obstruction: Benign prostatic hyperplasia causing incomplete bladder emptying and urinary stasis facilitates bacterial persistence and recurrent ascension into prostatic ducts. [3]

5. Relapsing Infection Pattern: Patients experience recurrent UTIs with same organism isolated on culture. Between acute episodes, bacteria persist asymptomatically in prostate, causing "ping-pong" pattern of infection. [3]

Chronic Pelvic Pain Syndrome (Type III)

CPPS pathophysiology remains incompletely understood, with heterogeneous mechanisms likely contributing in different patient subsets. [7,22,23,24]

Proposed Mechanisms

Exam Detail: 1. Post-Infectious Inflammatory Theory

Some CPPS cases may represent sequelae of previous bacterial prostatitis with persistent inflammation despite bacterial clearance. Evidence includes:

• Elevated inflammatory cytokines (IL-6, IL-8, TNF-alpha) in prostatic secretions of CPPS patients. [23]
• Detection of bacterial DNA (but not viable organisms) suggesting previous infection with persistent immune activation. [23]
• Clinical observation that some CPPS cases follow documented UTI or prostatitis episode. [7]

2. Autoimmune/Autoinflammatory Hypothesis

Molecular mimicry between prostatic antigens and bacterial antigens may trigger autoimmune prostatic inflammation:

• Antinuclear antibodies and anti-prostatic antibodies detected in subset of CPPS patients. [23]
• Experimental autoimmune prostatitis models in rodents demonstrate inflammation triggered by prostatic antigen exposure. [23]
• Response to anti-inflammatory therapies supports inflammatory component. [9]

3. Neuromuscular Theory (Pelvic Floor Dysfunction)

Strong evidence supports role of chronic pelvic floor muscle tension and spasm in CPPS:

• Myofascial trigger points identified in pelvic floor muscles (levator ani, obturator internus) of CPPS patients. [22]
• Electromyography demonstrates increased pelvic floor muscle activity and impaired relaxation. [22]
• Pelvic floor physiotherapy with biofeedback shows therapeutic benefit in randomised trials. [22]
• Patients demonstrate guarding behaviour, fear avoidance, and kinesiophobia contributing to muscle tension. [22]

4. Neuropathic Pain and Central Sensitisation

Chronic pain states involve neuroplastic changes with peripheral and central nervous system sensitisation:

• Peripheral sensitisation: Increased sensitivity of nociceptors in prostatic and pelvic tissues with reduced pain thresholds. [7]
• Central sensitisation: Altered pain processing in spinal cord and brain with amplification of pain signals (allodynia, hyperalgesia). [7]
• Functional MRI studies show altered brain activity patterns in pain processing regions of CPPS patients. [7]
• Neuropathic pain features (burning, shooting pain) common in CPPS, responding to neuropathic pain medications. [16]

5. Psychological and Psychosocial Factors

Bidirectional relationship exists between chronic pain and psychological distress:

• High prevalence of anxiety (40-60%) and depression (30-50%) in CPPS patients, rates significantly exceeding general population. [24]
• Catastrophising, pain-related fear, and maladaptive coping strategies predict worse outcomes. [24]
• Chronic pain causes psychological distress; conversely, psychological factors modulate pain perception and chronicity. [24]
• Stress activates hypothalamic-pituitary-adrenal axis with potential effects on prostatic inflammation. [24]

6. Bladder and Urethral Dysfunction

Some CPPS patients demonstrate bladder and urethral abnormalities:

• Detrusor overactivity and bladder hypersensitivity on urodynamic testing. [7]
• Urethral sphincter dysfunction with paradoxical contraction during voiding (dysfunctional voiding). [7]
• Overlap with interstitial cystitis/bladder pain syndrome in some patients. [7]

Type IIIA vs Type IIIB Distinction

The NIH classification subdivides CPPS into inflammatory (IIIA) and non-inflammatory (IIIB) based on white blood cell presence in expressed prostatic secretions or post-massage urine. [1,4]

Clinical Note: The IIIA vs IIIB distinction has limited therapeutic implications, as treatment approaches are similar regardless of inflammatory marker presence. This subdivision remains useful for research classification. [4]

---

4. Clinical Presentation

Acute Bacterial Prostatitis (Type I) - EMERGENCY PRESENTATION

Acute bacterial prostatitis presents as acute systemic infection requiring urgent assessment and hospitalisation. [2,13]

Symptoms

Signs

Exam Detail: Digital Rectal Examination in Acute Bacterial Prostatitis:

DRE findings are characteristic but examination must be gentle:

• Tenderness: Extreme pain on gentle palpation - patient may not tolerate full examination.
• Texture: Boggy, oedematous, indurated (rather than normal firm rubbery consistency).
• Temperature: May feel warm to examining finger due to inflammation.
• Size: Often enlarged due to oedema.
• Symmetry: Usually symmetrically affected (vs asymmetry in prostate cancer).

CRITICAL: Vigorous prostatic massage to obtain expressed prostatic secretions is ABSOLUTELY CONTRAINDICATED in acute prostatitis due to risk of:

• Inducing bacteraemia/septicaemia
• Precipitating septic shock
• Severe patient discomfort

Gentle palpation for diagnostic purposes only. [11]

Clinical Scenarios

Scenario 1: Classic Presentation 52-year-old man presents to Emergency Department with 24-hour history of fever (39.2°C), rigors, severe perineal pain, and urinary frequency with dysuria. Unable to pass urine for past 6 hours. Background of benign prostatic hyperplasia. On examination: temperature 39.1°C, heart rate 108 bpm, blood pressure 105/68 mmHg, suprapubic distension, DRE reveals exquisitely tender swollen prostate.

Scenario 2: Septic Presentation 68-year-old diabetic man with confusion, fever 40°C, rigors, blood pressure 88/52 mmHg, heart rate 128 bpm. Wife reports 2-day history of urinary symptoms. DRE reveals tender boggy prostate. Urosepsis secondary to acute bacterial prostatitis requiring ICU admission.

Chronic Bacterial Prostatitis (Type II)

Chronic bacterial prostatitis presents with recurrent urinary tract infections with same organism. [3]

Symptoms

Signs

• Digital Rectal Examination: May be normal or show mildly tender prostate. No acute inflammation features.
• Systemic Features: Absent between acute infection episodes.

Diagnostic Clue

Relapsing UTI Pattern: Same bacterial organism (identified by culture and antibiotic sensitivity pattern) causing recurrent symptomatic UTI episodes despite appropriate antibiotic treatment suggests chronic bacterial prostatitis with prostatic bacterial reservoir. [3]

Chronic Pelvic Pain Syndrome (Type III) - CPPS

CPPS is characterised by chronic pain in pelvic region for ≥3 months in absence of urinary tract infection or other identifiable pathology. [4,5]

Pain Characteristics

Associated Symptoms

NIH Chronic Prostatitis Symptom Index (NIH-CPSI)

Validated assessment tool quantifying symptom severity and quality of life impact: [4]

Domains:

1. Pain Domain (0-21 points): Location, frequency, severity
2. Urinary Symptoms Domain (0-10 points): Obstructive and irritative symptoms
3. Quality of Life Impact Domain (0-12 points): Interference with activities

Total Score: 0-43 points (higher scores = worse symptoms)

• Mild: 0-14
• Moderate: 15-29
• Severe: 30-43

Clinical Use: Baseline assessment, treatment response monitoring, research standardisation.

Physical Examination Findings

Exam Detail: Pelvic Floor Examination Findings in CPPS:

Specialist pelvic floor physiotherapists can identify:

• Myofascial Trigger Points: Tender points in levator ani, obturator internus, coccygeus, bulbospongiosus muscles that reproduce patient's pain when palpated.
• Pelvic Floor Hypertonicity: Increased resting tone, inability to relax pelvic floor muscles, paradoxical contraction during Valsalva.
• Guarding and Protective Muscle Spasm: Involuntary muscle tension in response to pain.

These findings support neuromuscular component and guide physiotherapy treatment. [22]

Asymptomatic Inflammatory Prostatitis (Type IV)

By definition, no symptoms attributable to prostate. [1]

Typical Discovery Scenarios:

• Elevated white blood cells in semen during infertility evaluation
• Inflammatory cells in expressed prostatic secretions during workup for elevated PSA
• Histological inflammation on prostate biopsy performed for PSA elevation or abnormal DRE

Management: Usually none required. If identified during infertility workup, trial of anti-inflammatory therapy may be considered though evidence is limited. [1]

---

5. Differential Diagnosis

Comprehensive differential diagnosis of male pelvic pain and lower urinary tract symptoms:

Exam Detail: Differentiating Bacterial Prostatitis from CPPS:

This is the most important distinction with major treatment implications:

Red Flags Suggesting Bacterial Infection:

• Fever or systemic symptoms
• Positive urine culture
• Response to antibiotics in previous episodes
• Recent urological procedure

Red Flags Suggesting Alternative Diagnosis:

• Haematuria (bladder cancer, stones)
• Hard nodular prostate (prostate cancer)
• Testicular mass (testicular cancer)
• Neurological symptoms (cauda equina, multiple sclerosis)

---

6. Investigations

Initial Assessment - All Patients

Acute Bacterial Prostatitis - Emergency Investigations

Exam Detail: Imaging in Acute Bacterial Prostatitis:

Routine imaging is NOT required for uncomplicated acute bacterial prostatitis. Imaging indications include: [13]

Transrectal Ultrasound (TRUS):

• Indication: Suspected prostatic abscess (persistent fever despite 48-72h IV antibiotics, palpable fluctuance).
• Findings: Hypoechoic lesion within prostate (abscess), oedematous enlarged gland (acute prostatitis).
• Sensitivity: 75-90% for abscess detection.
• Limitation: Uncomfortable for patient with tender prostate.

CT Pelvis with Contrast:

• Indication: Abscess suspected, TRUS not available or inconclusive.
• Findings: Rim-enhancing fluid collection in prostate, periprostatic inflammation.
• Advantage: Can assess for extraprostatic extension, pelvic abscess.

MRI Prostate:

• Indication: Complicated cases, abscess characterisation, surgical planning.
• Findings: T2 hyperintense abscess, diffusion restriction, post-contrast rim enhancement.
• Advantage: Superior soft tissue contrast, multiplanar imaging.

Chronic Bacterial Prostatitis - Diagnostic Testing

The "Two-Glass" or "Four-Glass" Test (Meares-Stamey Test)

Gold standard for localising bacterial infection to prostate, though rarely performed in current practice due to complexity. [3]

Four-Glass Test Protocol:

Diagnostic Criteria for Chronic Bacterial Prostatitis:

• Bacterial count in EPS or VB3 ≥10-fold higher than VB1 and VB2
• Same bacterial species isolated in recurrent episodes
• White blood cells ≥10 per high-power field in EPS or VB3

Two-Glass Simplified Test:

• Pre-Massage Urine (VB2): Midstream urine sample
• Post-Massage Urine (VB3): First 10 mL after prostatic massage
• If VB3 shows ≥10-fold increase in bacterial count or WBCs compared to VB2, localises to prostate

Practical Limitations:

• Time-consuming and technically challenging
• Requires skilled practitioner
• Patient discomfort during prostatic massage
• Increasingly replaced by empirical treatment based on clinical presentation and standard urine culture

Chronic Pelvic Pain Syndrome - Investigations

CPPS is primarily a clinical diagnosis of exclusion. Investigations aim to rule out bacterial infection and other pathology. [4,5]

Optional/Specialist Investigations in Refractory CPPS:

PSA Testing Considerations in Prostatitis

PSA is frequently elevated in prostatitis and must be interpreted carefully to avoid unnecessary anxiety and investigation. [14]

---

7. Management

Management Principles by NIH Category

Management strategies differ fundamentally between prostatitis categories based on underlying aetiology: [2,3,9,10]

Acute Bacterial Prostatitis (Type I) - EMERGENCY MANAGEMENT

Acute bacterial prostatitis requires immediate hospitalisation and intravenous antibiotics. [2,13]

Immediate Management (Emergency Department/Acute Admission)

1. Assessment and Resuscitation

Exam Detail: Sepsis Six (within 1 hour):

1. Give oxygen - Target saturations
2. Take blood cultures - Before antibiotics if possible
3. Give IV antibiotics - Broad-spectrum, less than 1 hour
4. Give IV fluids - Crystalloid resuscitation
5. Measure lactate - Tissue hypoperfusion marker
6. Measure urine output - Hourly monitoring

2. Antibiotic Therapy

Exam Detail: Principles of Antibiotic Selection in Acute Bacterial Prostatitis:

1. Spectrum: Gram-negative coverage (E. coli, Klebsiella, Pseudomonas, Proteus)
2. Prostatic Penetration: Fluoroquinolones achieve best prostatic levels; aminoglycosides (gentamicin) have poor penetration but excellent Gram-negative activity
3. Bactericidal Activity: Required for serious infection
4. Local Resistance Patterns: Consider local antibiograms
5. Patient Factors: Allergies, renal function, previous cultures

Initial Empirical IV Antibiotic Regimens (before culture results): [2,8,15]

Adjustment Based on Culture and Sensitivity:

• Narrow spectrum to most appropriate agent once sensitivities available
• Continue IV therapy until afebrile for 24-48 hours and clinically improving
• De-escalate from gentamicin early (renal toxicity, poor prostatic penetration) once oral switch possible

Step-Down to Oral Antibiotics:

Once patient afebrile for 24-48 hours, clinically improving, able to take oral medications, and sensitivities known: [8]

Duration Rationale: 4-6 weeks total antibiotic course required due to:

• Poor antibiotic penetration into prostatic tissue (blood-prostate barrier) [12]
• Risk of inadequate bacterial eradication with shorter courses
• Prevention of progression to chronic bacterial prostatitis
• Evidence from clinical trials showing higher cure rates with prolonged therapy [8]

3. Urinary Retention Management

Acute urinary retention occurs in 10-15% of acute bacterial prostatitis cases due to prostatic oedema compressing prostatic urethra. [13]

Suprapubic Catheter Advantages:

• Avoids traumatising inflamed prostatic urethra
• Reduces risk of bacteraemia from urethral instrumentation
• More comfortable for patient
• Easier trial of void (catheter can remain in situ)

4. Prostatic Abscess Management

Suspect prostatic abscess if: [13]

• Persistent fever despite 48-72 hours appropriate IV antibiotics
• Fluctuant mass on DRE
• Severe perineal pain
• Bacteraemia with positive blood cultures despite treatment

Diagnosis: Transrectal ultrasound (TRUS) or CT/MRI pelvis showing rim-enhancing fluid collection

Treatment:

• Continue IV antibiotics (adjust based on culture)
• Drainage required for abscesses > 1 cm:
  • Transrectal ultrasound-guided aspiration/drainage (percutaneous)
  • Transperineal drainage (if transrectal contraindicated)
  • Transurethral resection of prostate (TURP) (for large/multiloculated abscesses)
• Urology referral for drainage procedure

Admission Criteria and Disposition

Chronic Bacterial Prostatitis (Type II)

Management centers on prolonged antibiotic therapy with focus on agents achieving good prostatic penetration. [3,8,12]

Antibiotic Therapy

First-Line Oral Antibiotics:

Duration: Minimum 4-6 weeks; some guidelines recommend up to 12 weeks for refractory cases. [3,8]

Post-Treatment Assessment:

• Repeat urine culture 2 weeks post-treatment completion
• Repeat 2-glass test if available
• Clinical symptom assessment

Recurrent/Refractory Cases

Chronic Pelvic Pain Syndrome (Type III) - Multimodal Management

CPPS requires individualised, multimodal approach acknowledging heterogeneous pathophysiology. No single therapy is universally effective. [9,10,16,22,24]

Pharmacological Therapies

Exam Detail: Evidence-Based Pharmacological Interventions:

The evidence base for CPPS pharmacotherapy is variable, with most therapies showing modest benefit in subsets of patients.

1. Alpha-Blockers

Evidence: Meta-analyses show modest symptom improvement (NIH-CPSI reduction 4-6 points) in 30-40% of patients, particularly those with voiding symptoms. [9] Side effects: postural hypotension, retrograde ejaculation (rare with tamsulosin).

2. Anti-Inflammatory Agents

Note: Quercetin is a bioflavonoid with anti-inflammatory and antioxidant properties; small studies suggest benefit but requires further validation. [26]

3. Neuropathic Pain Modulators

For patients with neuropathic pain features (burning, shooting pain, allodynia): [16]

Duration: 8-12 week trial at therapeutic dose required to assess efficacy.

4. Antibiotics (Empirical Trial)

Despite absence of proven infection, some clinicians trial antibiotics in CPPS based on post-infectious theory. Evidence is weak. [9]

Conclusion: Antibiotics NOT routinely recommended for CPPS; consider only if clinical suspicion of undetected infection or previous partial response.

5. 5-Alpha Reductase Inhibitors (5-ARIs)

Limited evidence; may be considered in men with concurrent BPH.

Non-Pharmacological Therapies

1. Pelvic Floor Physiotherapy

Strong evidence supports pelvic floor physiotherapy as cornerstone of CPPS management. [22]

Outcomes: Randomised controlled trials show 50-70% of patients experience significant symptom improvement with specialist pelvic floor physiotherapy. [22]

2. Psychological Support and Cognitive Behavioural Therapy (CBT)

Addressing psychological comorbidity and maladaptive pain beliefs is essential. [24]

3. Lifestyle Modifications

4. Other Emerging Therapies

Multimodal Treatment Algorithm for CPPS

CPPS DIAGNOSIS CONFIRMED
(Pain ≥3 months, negative cultures, exclude other pathology)
            ↓
INITIAL MANAGEMENT (8-12 weeks)
            ↓
    ┌───────────────┼───────────────┐
    ↓               ↓               ↓
ALPHA-BLOCKER    NSAIDs/         PELVIC FLOOR
(Tamsulosin)     Quercetin       PHYSIOTHERAPY
400 mcg OD       PRN/regular     Weekly sessions
    ↓               ↓               ↓
        REASSESS SYMPTOMS
        (NIH-CPSI score)
                ↓
    ┌───────────────┴───────────────┐
    ↓                               ↓
IMPROVEMENT                    NO/MINIMAL IMPROVEMENT
Continue effective             ↓
therapies                  ADD SECOND-LINE THERAPIES
Monitor long-term                  ↓
                    ┌──────────────┼──────────────┐
                    ↓              ↓              ↓
            NEUROPATHIC PAIN   PSYCHOLOGICAL  EMPIRICAL
            MODULATOR          SUPPORT (CBT)  ANTIBIOTIC TRIAL
            (Amitriptyline/                   (4-6 weeks)
             Pregabalin)                      (limited evidence)
                    ↓              ↓              ↓
                REASSESS 12-16 WEEKS
                        ↓
            ┌───────────┴───────────┐
            ↓                       ↓
    IMPROVEMENT               REFRACTORY
    Continue therapies        ↓
    Long-term management  SPECIALIST PAIN SERVICE
                          - Pain clinic review
                          - Consider emerging therapies
                          - Multidisciplinary approach

Setting Realistic Expectations

Critical counselling points for CPPS patients: [4,5,10]

1. CPPS is a chronic condition: Complete "cure" is uncommon; focus on symptom management and quality of life improvement.
2. Variable treatment response: Therapies that work for some patients may not work for others; trial-and-error approach.
3. Multimodal therapy more effective: Combining treatments (e.g., alpha-blocker + physiotherapy + CBT) more likely to help than single therapy.
4. Symptom fluctuation is normal: Expect good days and bad days; stress, sitting, activity levels affect symptoms.
5. Long-term self-management: Physiotherapy exercises, stress management, lifestyle modifications are ongoing.
6. Psychological impact is real: Acknowledging anxiety/depression and seeking support is important.

Asymptomatic Inflammatory Prostatitis (Type IV)

No treatment required in most cases. [1]

Exceptions:

• Infertility investigation: If elevated WBCs in semen, may trial anti-inflammatory therapy or antibiotics (limited evidence).
• Elevated PSA concern: Reassure patient; repeat PSA after 4-6 weeks if infection treated.

---

8. Complications

Acute Bacterial Prostatitis Complications

Chronic Bacterial Prostatitis Complications

CPPS Complications

---

9. Prognosis and Outcomes

Acute Bacterial Prostatitis

Prognostic Factors:

• Good: Early treatment, antibiotic-sensitive organism, no abscess, immunocompetent
• Poor: Delayed presentation, prostatic abscess, immunosuppression, multi-resistant organisms

Chronic Bacterial Prostatitis

Chronic Pelvic Pain Syndrome (CPPS)

CPPS has highly variable prognosis with no curative treatment. Quality of life significantly impacted. [4,5,10,19]

Prognostic Factors Predicting Better Outcomes:

• Shorter symptom duration (less than 2 years)
• Predominant LUTS rather than pain
• Absence of psychological comorbidity
• Engagement with multimodal therapy (physiotherapy + pharmacotherapy)
• Pelvic floor dysfunction (responds to physiotherapy)

Prognostic Factors Predicting Poorer Outcomes:

• Long symptom duration (> 5 years)
• Severe baseline pain (NIH-CPSI > 30)
• Major depression or anxiety
• Pain catastrophising and maladaptive coping
• Multiple previous failed treatments

Long-Term Follow-Up

---

10. Prevention

Prevention of Bacterial Prostatitis

CPPS Prevention

No established prevention strategies (aetiology unclear). Theoretical approaches:

• Prompt treatment of bacterial prostatitis to prevent chronic pain sensitisation
• Stress management and psychological wellbeing
• Avoid prolonged perineal pressure (cycling modifications)

---

11. Evidence and Guidelines

Key Guidelines

Landmark Studies and Systematic Reviews

Evidence Levels for Key Interventions

---

12. Patient and Layperson Explanation

What is Prostatitis?

Prostatitis means inflammation or infection of the prostate gland, a small gland (about the size of a walnut) located just below the bladder in men. The prostate surrounds part of the tube that carries urine out of the body (the urethra).

There are different types of prostatitis:

1. Acute Bacterial Prostatitis: A sudden, severe infection of the prostate caused by bacteria. This causes high fever, severe pain in the lower abdomen/back passage area, and difficulty urinating. This is a medical emergency requiring hospital admission and intravenous antibiotics.

2. Chronic Bacterial Prostatitis: A long-term infection of the prostate that keeps coming back. It causes recurring urine infections with the same bacteria.

3. Chronic Pelvic Pain Syndrome (CPPS): The most common type (9 out of 10 cases). This causes long-term (more than 3 months) pain in the pelvic area, genital area, or lower back, along with urinary symptoms. Unlike the bacterial types, no infection is found. The cause is not fully understood but may involve muscle tension, nerve sensitivity, or previous infection triggering ongoing inflammation.

4. Asymptomatic Inflammatory Prostatitis: Inflammation found by chance during tests for other reasons (like fertility tests or PSA blood tests). This type causes no symptoms and usually doesn't need treatment.

Is Prostatitis Serious?

• Acute bacterial prostatitis is serious and can be life-threatening if not treated quickly. With prompt antibiotics, nearly all men make a full recovery.
• Chronic bacterial prostatitis is not immediately dangerous but can be frustrating due to recurring infections.
• Chronic pelvic pain syndrome is not life-threatening but can significantly affect quality of life, causing ongoing pain, urinary problems, sexual difficulties, and emotional distress.

What Causes Prostatitis?

• Bacterial types: Caused by bacteria (usually E. coli, the same bacteria that causes urine infections) traveling up from the urethra into the prostate.
• Chronic pelvic pain syndrome: The cause is unclear. It may involve:
  • Muscle tension in the pelvic floor muscles
  • Nerve sensitivity causing pain signals even without infection
  • Previous infection that has been cleared but left the nerves "sensitised"
  • Stress and psychological factors affecting pain perception

What are the Symptoms?

Acute Bacterial Prostatitis:

• High fever, chills, feeling very unwell
• Severe pain in the lower abdomen, back passage area, or lower back
• Burning pain when urinating, needing to urinate frequently and urgently
• Sometimes unable to pass urine at all

Chronic Pelvic Pain Syndrome:

• Long-term pain (lasting months or years) in the pelvic area, genitals, or lower back
• Pain may be constant or come and go
• Urinary symptoms: frequency, urgency, weak stream
• Pain during or after ejaculation
• Impact on mood: anxiety or low mood due to ongoing symptoms

How is Prostatitis Diagnosed?

• Urine test: To check for bacteria and infection
• Blood tests: To check for signs of infection (in acute cases)
• Examination: Your doctor will gently examine the prostate via the back passage (rectal examination). In acute prostatitis, the prostate feels very tender and swollen. In chronic pelvic pain syndrome, it usually feels normal or only mildly tender.
• Further tests: Sometimes additional urine samples after prostate massage, or scans if an abscess is suspected.

How is Prostatitis Treated?

Acute Bacterial Prostatitis:

• Hospital admission
• Intravenous antibiotics initially, then switch to tablets
• Total antibiotic course of 4-6 weeks (longer than a typical infection because antibiotics don't penetrate the prostate easily)
• If you can't pass urine, a catheter (tube) may be inserted (usually through the lower abdomen rather than the urethra)

Chronic Bacterial Prostatitis:

• Antibiotic tablets for 4-6 weeks
• Sometimes longer courses or low-dose antibiotics long-term if infections keep coming back

Chronic Pelvic Pain Syndrome: This is more challenging to treat as there's no single cure. Treatment involves trying different approaches:

• Medications:
  • Alpha-blockers (e.g., tamsulosin) to relax the prostate and bladder
  • Painkillers (anti-inflammatories or nerve pain medications)
  • Sometimes a trial of antibiotics (though evidence is limited)
• Physiotherapy: Specialist pelvic floor physiotherapy to release muscle tension and teach relaxation techniques
• Psychological support: Cognitive behavioural therapy (CBT) or counselling to help manage chronic pain, anxiety, and low mood
• Lifestyle changes: Avoiding prolonged sitting, stress management, warm baths for symptom relief

Important: CPPS is a chronic condition. The goal is to improve symptoms and quality of life rather than achieve a complete "cure." Different treatments work for different people, so finding what helps you may involve trial and error.

Does Prostatitis Mean I Have Prostate Cancer?

No. Prostatitis is inflammation or infection of the prostate, not cancer. However, prostatitis can cause your PSA blood test (a test sometimes used to screen for prostate cancer) to rise temporarily. If you've had prostatitis, your doctor will wait 4-6 weeks after treatment before checking PSA again for cancer screening.

Can Prostatitis Affect My Sex Life?

Yes, prostatitis (especially CPPS) can cause:

• Pain during or after ejaculation
• Erectile dysfunction
• Reduced sex drive
• Anxiety about sexual activity

Discussing these concerns with your doctor is important. Treatments for pain, addressing anxiety, and sometimes medications for erectile dysfunction (like sildenafil/Viagra) can help.

Will Prostatitis Affect My Fertility?

Bacterial prostatitis can sometimes affect sperm quality temporarily. Once the infection is treated, fertility usually returns to normal. If you're concerned about fertility, discuss this with your doctor—a semen analysis test can check sperm quality.

How Can I Manage Symptoms at Home?

• Warm baths: Can help relieve pelvic pain
• Regular ejaculation: Some men find this helps (evidence is mixed)
• Avoid prolonged sitting: Take breaks to stand and move
• Stress management: Relaxation techniques, exercise, mindfulness
• Avoid triggers: Some men find alcohol, caffeine, or spicy foods worsen symptoms—keep a diary to identify your triggers
• Stay hydrated: Don't restrict fluids (this doesn't help and may worsen symptoms)

When Should I Seek Urgent Medical Help?

Go to the Emergency Department or call 999 if you have:

• High fever with severe pelvic/back passage pain
• Unable to pass urine for several hours
• Feeling very unwell, dizzy, or confused
• Severe pain not controlled by painkillers

These could be signs of acute bacterial prostatitis or complications requiring urgent treatment.

Where Can I Find Support?

Living with chronic prostatitis (especially CPPS) can be isolating and frustrating. Consider:

• Prostatitis support groups: Online forums and charities (e.g., Prostatitis Foundation)
• Mental health support: Your GP can refer you to counselling or psychological therapy
• Specialist urology clinics: For complex or refractory cases
• Chronic pain services: Multidisciplinary teams experienced in managing long-term pain

---

13. References

Primary Sources

1. Krieger JN, Nyberg L Jr, Nickel JC. NIH consensus definition and classification of prostatitis. JAMA. 1999;282(3):236-237. doi:10.1001/jama.282.3.236

2. Lipsky BA, Byren I, Hoey CT. Treatment of bacterial prostatitis. Clin Infect Dis. 2010;50(12):1641-1652. doi:10.1086/652861

3. Schaeffer AJ, Anderson RU, Krieger JN, et al. Chronic bacterial prostatitis. In: Prostatitis and Related Conditions, Orchitis, and Epididymitis. AUA Update Series. 2012;31:1-16.

4. Nickel JC, Downey J, Hunter D, Clark J. Prevalence of prostatitis-like symptoms in a population based study using the National Institutes of Health chronic prostatitis symptom index. J Urol. 2001;165(3):842-845. doi:10.1016/S0022-5347(05)66541-X

5. Schaeffer AJ. Clinical practice. Chronic prostatitis and the chronic pelvic pain syndrome. N Engl J Med. 2006;355(16):1690-1698. doi:10.1056/NEJMcp060423

6. Etienne M, Chavanet P, Sibert L, et al. Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis. BMC Infect Dis. 2008;8:12. doi:10.1186/1471-2334-8-12

7. Pontari MA, Ruggieri MR. Mechanisms in prostatitis/chronic pelvic pain syndrome. J Urol. 2004;172(3):839-845. doi:10.1097/01.ju.0000136002.76898.04

8. Naber KG, Bergman B, Bishop MC, et al. EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol. 2001;40(5):576-588. doi:10.1159/000049840

9. Anothaisintawee T, Attia J, Nickel JC, et al. Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA. 2011;305(1):78-86. doi:10.1001/jama.2010.1913

10. Franco JVA, Turk T, Jung JH, et al. Non-pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Cochrane Database Syst Rev. 2018;5(5):CD012551. doi:10.1002/14651858.CD012551.pub3

11. Roberts RO, Lieber MM, Rhodes T, Girman CJ, Bostwick DG, Jacobsen SJ. Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men. Urology. 1998;51(4):578-584. doi:10.1016/s0090-4295(98)00034-x

12. Wagenlehner FM, Naber KG. Fluoroquinolone antimicrobial agents in the treatment of prostatitis and recurrent urinary tract infections in men. Curr Infect Dis Rep. 2005;7(1):9-16. doi:10.1007/s11908-005-0048-5

13. Olivera P, Bañuelos R, García-Rodríguez J, et al. Acute bacterial prostatitis: diagnostic and therapeutic approach. Actas Urol Esp. 2015;39(3):154-160. doi:10.1016/j.acuro.2014.05.003

14. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995;154(2 Pt 1):407-413. doi:10.1016/S0022-5347(01)67064-2

15. Naber KG, Sorgel F. Antibiotic therapy—rationale and evidence for optimal drug concentrations in prostatic and seminal fluid and in prostatic tissue. Andrologia. 2003;35(6):331-335. doi:10.1111/j.1439-0272.2003.tb00866.x

16. Passavanti MB, Pota V, Sansone P, Aurilio C, De Nardis L, Pace MC. Chronic pelvic pain: assessment, evaluation, and objectivation. Pain Res Treat. 2017;2017:9472925. doi:10.1155/2017/9472925

17. Collins MM, Stafford RS, O'Leary MP, Barry MJ. How common is prostatitis? A national survey of physician visits. J Urol. 1998;159(4):1224-1228. doi:10.1016/S0022-5347(01)63564-X

18. Mehik A, Hellström P, Lukkarinen O, Sarpola A, Järvelin M. Epidemiology of prostatitis in Finnish men: a population-based cross-sectional study. BJU Int. 2000;86(4):443-448. doi:10.1046/j.1464-410x.2000.00836.x

19. Wenninger K, Heiman JR, Rothman I, Berghuis JP, Berger RE. Sickness impact of chronic nonbacterial prostatitis and its correlates. J Urol. 1996;155(3):965-968. PMID:8583619

20. Krieger JN, Riley DE. Prostatitis: what is the role of infection. Int J Antimicrob Agents. 2002;19(6):475-479. doi:10.1016/s0924-8579(02)00087-7

21. Zani EL, Clark OA, Rodrigues Netto N Jr. Antibiotic prophylaxis for transrectal prostate biopsy. Cochrane Database Syst Rev. 2011;(5):CD006576. doi:10.1002/14651858.CD006576.pub2

22. Anderson RU, Wise D, Sawyer T, Chan CA. Sexual dysfunction in men with chronic prostatitis/chronic pelvic pain syndrome: improvement after trigger point release and paradoxical relaxation training. J Urol. 2006;176(4 Pt 1):1534-1538. doi:10.1016/j.juro.2006.06.010

23. Shoskes DA, Katz E. Multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome. Curr Urol Rep. 2005;6(4):296-299. doi:10.1007/s11934-005-0029-x

24. Tripp DA, Nickel JC, Wang Y, et al. Catastrophizing and pain-contingent rest predict patient adjustment in men with chronic prostatitis/chronic pelvic pain syndrome. J Pain. 2006;7(10):697-708. doi:10.1016/j.jpain.2006.03.006

25. Roberts RO, Jacobson DJ, Girman CJ, Rhodes T, Lieber MM, Jacobsen SJ. Prevalence of prostatitis-like symptoms in a community based cohort of older men. J Urol. 2002;168(6):2467-2471. doi:10.1016/S0022-5347(05)64163-0

26. Shoskes DA, Zeitlin SI, Shahed A, Rajfer J. Quercetin in men with category III chronic prostatitis: a preliminary prospective, double-blind, placebo-controlled trial. Urology. 1999;54(6):960-963. doi:10.1016/s0090-4295(99)00358-1

27. Nickel JC, Downey J, Pontari MA, Shoskes DA, Zeitlin SI. A randomized placebo-controlled multicentre study to evaluate the safety and efficacy of finasteride for male chronic pelvic pain syndrome (category IIIA chronic nonbacterial prostatitis). BJU Int. 2004;93(7):991-995. doi:10.1111/j.1464-410X.2004.04788.x

28. Lee SW, Liong ML, Yuen KH, et al. Acupuncture versus sham acupuncture for chronic prostatitis/chronic pelvic pain syndrome. Am J Med. 2008;121(1):79.e1-7. doi:10.1016/j.amjmed.2007.07.033

29. Bonkat G, Bartoletti R, Bruyère F, et al. EAU Guidelines on Urological Infections. European Association of Urology; 2023. Available at: https://uroweb.org/guidelines/urological-infections

30. Nickel JC, Shoskes D, Wagenlehner FM. Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): the studies, the evidence, and the impact. World J Urol. 2013;31(4):747-753. doi:10.1007/s00345-013-1062-y

---

14. Examination Focus

High-Yield Exam Topics

Classification

Question: What is the most common category of prostatitis?

Answer: Chronic Pelvic Pain Syndrome (CPPS) - NIH Category III, accounting for approximately 90-95% of all prostatitis cases. [4,5]

Question: Describe the NIH classification of prostatitis.

Answer:

• Type I (Acute Bacterial Prostatitis): Acute bacterial infection with systemic features (fever, rigors), positive urine culture, requires urgent IV antibiotics.
• Type II (Chronic Bacterial Prostatitis): Recurrent urinary tract infections with same bacterial organism, bacteria in prostatic secretions.
• Type III (Chronic Pelvic Pain Syndrome - CPPS): Chronic pelvic pain ≥3 months without bacterial infection. Subdivided into:
  • "Type IIIA (Inflammatory): White blood cells in prostatic secretions"
  • "Type IIIB (Non-inflammatory): No white blood cells"
• Type IV (Asymptomatic Inflammatory Prostatitis): Incidental finding of prostatic inflammation without symptoms. [1]

Acute Bacterial Prostatitis

Question: A 58-year-old man presents with fever (39.5°C), rigors, severe perineal pain, and dysuria. On examination, he has a temperature of 39.3°C, heart rate 112 bpm, blood pressure 102/65 mmHg. Digital rectal examination reveals an exquisitely tender, boggy prostate. What is the diagnosis and immediate management?

Answer: Diagnosis: Acute bacterial prostatitis (NIH Type I)

Immediate Management:

1. Assess for sepsis: Check lactate, monitor vital signs, NEWS2 score
2. Investigations: Blood cultures, urine culture, FBC, CRP, U&E (before antibiotics if possible)
3. IV fluid resuscitation if hypotensive
4. IV antibiotics (within 1 hour): Ciprofloxacin 400 mg IV 12-hourly OR Gentamicin 5-7 mg/kg IV 24-hourly + Amoxicillin 1-2g IV 8-hourly
5. Admission to hospital ward or HDU/ICU if septic
6. Urinary catheter if retention (suprapubic catheter preferred)
7. Step down to oral antibiotics once afebrile 24-48h and improving (ciprofloxacin 500 mg PO BD)
8. Total duration: 4-6 weeks antibiotics [2,8,13]

Question: Why is vigorous prostatic massage contraindicated in acute bacterial prostatitis?

Answer: Vigorous prostatic massage in acute bacterial prostatitis can precipitate:

• Bacteraemia/septicaemia: Forcing bacteria into bloodstream
• Septic shock: Systemic inflammatory response
• Severe patient discomfort: Extremely tender prostate

DRE should be gentle palpation only for diagnostic purposes. Prostatic massage to obtain expressed prostatic secretions (EPS) is reserved for chronic prostatitis evaluation. [11]

Question: What organism causes the majority of acute bacterial prostatitis cases?

Answer: Escherichia coli (uropathogenic E. coli - UPEC) causes 70-80% of acute bacterial prostatitis cases. Other Gram-negative organisms include Klebsiella, Pseudomonas, Proteus, and Enterococcus. In young sexually active men, consider Chlamydia trachomatis and Neisseria gonorrhoeae. [6]

Question: Why is a 4-6 week course of antibiotics required for bacterial prostatitis?

Answer: Prolonged antibiotic therapy (4-6 weeks) is required due to:

1. Poor prostatic penetration: Blood-prostate barrier limits antibiotic diffusion into prostatic tissue
2. Bacterial biofilms: Bacteria form biofilm communities in prostatic acini, requiring prolonged exposure
3. Prostatic calculi: Calcified deposits harbour bacteria
4. Prevention of chronic infection: Shorter courses result in high relapse rates and progression to chronic bacterial prostatitis

Fluoroquinolones (ciprofloxacin, levofloxacin) and trimethoprim achieve best prostatic tissue concentrations. [8,12]

Chronic Pelvic Pain Syndrome

Question: What is the pathophysiology of chronic pelvic pain syndrome (CPPS)?

Answer: CPPS pathophysiology is poorly understood and likely heterogeneous. Proposed mechanisms include:

1. Neuromuscular dysfunction: Pelvic floor muscle spasm, myofascial trigger points causing pain and voiding dysfunction [22]
2. Neuropathic pain/central sensitisation: Altered pain processing with peripheral and central nervous system sensitisation [7]
3. Post-infectious inflammation: Persistent inflammation following bacterial infection despite bacterial clearance [23]
4. Autoimmune mechanisms: Molecular mimicry between bacterial and prostatic antigens [23]
5. Psychological factors: Bidirectional relationship between chronic pain and anxiety/depression [24]

No single mechanism explains all cases; different pathways likely contribute in different patients. [7]

Question: What is the evidence-based multimodal management approach for CPPS?

Answer:

1. Alpha-blockers (e.g., tamsulosin 400 mcg OD): Relax prostatic smooth muscle; moderate evidence for symptom improvement [9]
2. Pelvic floor physiotherapy: Myofascial release, biofeedback, relaxation training; strong evidence [22]
3. Neuropathic pain modulators (e.g., amitriptyline, pregabalin): For neuropathic pain features [16]
4. Cognitive behavioural therapy (CBT): Addresses pain catastrophising, anxiety, depression [24]
5. Anti-inflammatory agents: NSAIDs, quercetin (limited evidence) [26]
6. NOT routinely recommended: Antibiotics (no proven benefit in absence of infection) [9]

Key: Multimodal approach combining treatments more effective than monotherapy. Set realistic expectations—complete cure uncommon; focus on symptom improvement and quality of life. [10]

Question: How do you differentiate bacterial prostatitis from CPPS?

Answer:

Critical distinction as treatment differs fundamentally: antibiotics for bacterial prostatitis vs. multimodal therapy for CPPS. [3,4,5]

Viva Scenarios

Viva Question 1: You are the urology registrar on-call. A 62-year-old diabetic man is admitted with acute bacterial prostatitis. He has received IV ciprofloxacin for 72 hours but remains febrile (38.9°C) with persistent severe perineal pain. What is your differential diagnosis and management plan?

Model Answer:

Differential Diagnosis:

1. Prostatic abscess (most likely given persistent fever despite antibiotics)
2. Inadequate antibiotic choice (resistant organism)
3. Alternative/concurrent infection source (e.g., pyelonephritis, epididymo-orchitis)
4. Non-infectious complication (e.g., venous thromboembolism)

Immediate Management:

1. Clinical reassessment: Repeat DRE (looking for fluctuance suggesting abscess), examine testes, check for DVT signs
2. Investigations:
   • Repeat blood cultures, urine culture
   • Inflammatory markers (FBC, CRP trending)
   • Transrectal ultrasound (TRUS) or CT pelvis to look for prostatic abscess
   • Review initial culture sensitivities
3. Antibiotic review: Check sensitivities; consider broader spectrum or change to alternative (e.g., gentamicin + amoxicillin if not already used)
4. If abscess confirmed:
   • Drainage required: TRUS-guided aspiration/drainage, or transurethral resection of prostate (TURP) for large/multiloculated abscesses
   • Continue IV antibiotics
   • Urology consultant involvement for drainage planning [13]

Viva Question 2: A 42-year-old man has been diagnosed with chronic pelvic pain syndrome. He has seen multiple doctors, tried several antibiotics without benefit, and is becoming depressed. How would you counsel him and plan management?

Model Answer:

Counselling:

1. Acknowledge distress: "I understand this has been very difficult and frustrating for you."
2. Explain diagnosis: "You have chronic pelvic pain syndrome, which is pain in the pelvic area without an infection. It's the most common type of prostatitis, affecting about 90% of men with prostatitis symptoms."
3. Explain aetiology uncertainty: "The exact cause isn't fully understood—it likely involves muscle tension, nerve sensitivity, and possibly previous inflammation. It's not an infection, which is why antibiotics haven't helped."
4. Set realistic expectations: "There's no single 'cure,' but we have several treatments that can significantly improve your symptoms and quality of life. The goal is to manage symptoms, not necessarily eliminate them completely."
5. Address depression: "Living with chronic pain can affect mood—it's a normal response. Treating low mood as part of your overall care is important."

Management Plan:

1. Multimodal therapy:
   • Alpha-blocker (tamsulosin 400 mcg OD) for 8-12 weeks
   • Pelvic floor physiotherapy: Refer to specialist physiotherapist for assessment and biofeedback
   • Psychological support: CBT referral to address catastrophising, coping strategies, depression
   • Neuropathic pain modulator: Consider amitriptyline 10 mg nocte, titrating up
2. Lifestyle advice: Avoid prolonged sitting, stress management, warm baths, trial of dietary modification
3. Review in 8-12 weeks: Assess NIH-CPSI score, adjust therapies based on response
4. Involve chronic pain service if refractory: Multidisciplinary approach [9,10,24]

Viva Question 3: Why is suprapubic catheterisation preferred over urethral catheterisation in acute urinary retention complicating acute bacterial prostatitis?

Model Answer:

Suprapubic catheter (SPC) is preferred because:

1. Avoids urethral trauma: Urethral catheter insertion through inflamed, oedematous prostatic urethra risks:
   • Mucosal injury and bleeding
   • Further bacterial seeding into prostatic tissue
   • Bacteraemia from instrumentation
2. Reduced infection risk: Bypasses contaminated urethra
3. Patient comfort: Less discomfort with SPC than urethral catheter when prostate severely inflamed
4. Trial of void easier: SPC can remain capped for trial of void once inflammation settles

Urethral catheter only if SPC not feasible/available; use small-bore catheter, gentle insertion, single attempt. [13]

Clinical Pearls for Examinations

1. Acute bacterial prostatitis triad: Fever + dysuria/LUTS + exquisitely tender prostate = admit, IV antibiotics, 4-6 weeks total
2. CPPS is a diagnosis of exclusion: Rule out infection, cancer, other pathology before diagnosing
3. PSA unreliable in active prostatitis: Defer PSA testing for 4-6 weeks post-treatment
4. Multimodal CPPS management: Alpha-blocker + physiotherapy + psychological support
5. Prostatic massage contraindicated in acute prostatitis: Risk of bacteraemia/sepsis
6. Fluoroquinolones penetrate prostate best: First-line for bacterial prostatitis (if sensitive)
7. CPPS ≠ infection: Antibiotics not routinely recommended
8. Depression/anxiety screening essential in CPPS: High prevalence, impacts outcomes

---

Medical Disclaimer: MedVellum content is for educational purposes and clinical reference. Clinical decisions should account for individual patient circumstances, local guidelines, antimicrobial resistance patterns, and patient comorbidities. Always consult appropriate specialists for complex or refractory cases.